Analysts Set $10.33 Price Target for Exicure, Inc. (NYSE:XCUR)

Shares of Exicure, Inc. (NYSE:XCUR) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that cover the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokers have set a 12 month consensus target price of $10.33 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Exicure an industry rank of 56 out of 255 based on the ratings given to its competitors.

Separately, HC Wainwright reiterated a “buy” rating on shares of Exicure in a research report on Wednesday, November 6th.

NYSE XCUR traded up $0.02 during trading on Tuesday, hitting $2.51. 952 shares of the company’s stock traded hands, compared to its average volume of 67,962. Exicure has a 12-month low of $1.62 and a 12-month high of $4.20.

Exicure (NYSE:XCUR) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.53 million for the quarter.

Exicure Company Profile

Exicure, Inc, a clinical-stage biotechnology company, develops gene regulatory and immuno-oncology therapeutics based on spherical nucleic acid (SNA) technology. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis.

See Also: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on Exicure (XCUR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.